As of 11:31 AM on the 22nd, Celltrion is trading at 313,000 KRW, up 0.32% from the previous day. This represents an 18.49% decline compared to January 12. Celltrion is known as a protein and biopharmaceutical manufacturing company.
Today, foreigners have net sold 15,992 shares of Celltrion, and institutions have net sold 17,000 shares, according to provisional data. Over the past five days, individual investors have net bought 178,226 shares, while foreigners and institutions have net bought 17,860 shares and net sold 214,254 shares, respectively.
On January 20, Celltrion became a market topic with the headline "Rebound six trading days after the announcement of the COVID-19 treatment clinical trial."


※ Source: AI Investment Assistant AI Rassiro
※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
